Deutsch English Français

Contact

EP3932914

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3932914

EP3932914 - ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 19.04.2024 Database last updated on 13.11.2024
Former	Examination is in progress Status updated on 16.06.2023
Former	Request for examination was made Status updated on 08.07.2022
Former	The application has been published Status updated on 03.12.2021
Most recent event Tooltip	19.04.2024	Application deemed to be withdrawn	published on 22.05.2024 [2024/21]
Applicant(s)	For all designated states Valo Health, Inc. 399 Boylston St. Boston, MA 02116 / US
	[2022/01]
Inventor(s)	01 / BAIR, Kenneth W. Wellesley, 02482 / US
	02 / BARCZAK, Nicholas Waterford, 06385 / US
	03 / HAN, Bingsong North Haven, 06473 / US
	04 / LANCIA, David R., Jr. Boston, 02131 / US
	05 / LIU, Cuixian Madison, 06443 / US
	06 / MARTIN, Matthew W. Arlington, 02474 / US
	07 / NG, Pui Yee Waltham, 02453 / US
	08 / RUDNITSKAYA, Aleksandra Roslindale, 02131 / US
	09 / THOMASON, Jennifer R. Clinton, 01510 / US
	10 / ZABLOCKI, Mary-Margaret Revere, 02151 / US
	11 / ZHENG, Xiaozhang Lexington, 02421 / US
	[2022/01]
Representative(s)	Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[2022/01]
Application number, filing date	21169630.7	11.03.2016
	[2022/01]
Priority number, date	US201562132895P	13.03.2015 Original published format: US 201562132895 P
	US201562184335P	25.06.2015 Original published format: US 201562184335 P
	US201562270371P	21.12.2015 Original published format: US 201562270371 P
	[2022/01]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP3932914
	Date:	05.01.2022
	Language:	EN
	[2022/01]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	06.10.2021
Classification	IPC:	C07D401/14, C07D213/75, C07C259/06, A61P35/00, C07D213/81, C07D215/12, C07C275/30, C07D317/68, C07D231/14, C07D231/18, C07D233/36, C07D233/38, C07D333/70, C07D233/68, C07D401/04	[2022/01]
	CPC:	C07C259/06 (EP,US); C07D235/14 (EP,KR,US); A61K31/185 (US); A61K31/277 (US); A61K31/397 (US); A61K31/4035 (US); (+) A61K31/407 (US); A61K31/417 (US); A61K31/4184 (KR,US); A61K31/435 (US); A61K31/438 (US); A61K31/44 (US); A61K31/4439 (KR,US); A61K31/451 (US); A61K31/495 (US); A61K31/5377 (KR,US); A61P1/00 (EP); A61P1/04 (EP); A61P1/16 (EP); A61P11/02 (EP); A61P11/06 (EP); A61P13/02 (EP); A61P17/00 (EP); A61P17/02 (EP); A61P17/06 (EP); A61P19/02 (EP); A61P19/04 (EP); A61P21/04 (EP); A61P25/00 (EP); A61P25/08 (EP); A61P25/14 (EP); A61P25/16 (EP); A61P25/28 (EP); A61P27/14 (EP); A61P27/16 (EP); A61P29/00 (EP); A61P3/00 (EP); A61P3/04 (EP); A61P3/10 (EP); A61P31/00 (EP); A61P31/04 (EP); A61P31/12 (EP); A61P31/14 (EP); A61P31/16 (EP); A61P31/20 (EP); A61P31/22 (EP); A61P33/00 (EP); A61P33/06 (EP); A61P35/00 (EP); A61P35/02 (EP); A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP); A61P7/00 (EP); A61P7/06 (EP); A61P9/00 (EP); A61P9/04 (EP); A61P9/10 (EP); A61P9/14 (EP); C07D207/10 (EP,US); C07D207/267 (EP,US); C07D209/08 (EP,US); C07D209/42 (EP,US); C07D209/44 (EP,US); C07D209/46 (EP,US); C07D211/16 (EP,US); C07D211/58 (EP,US); C07D213/56 (EP,US); C07D213/65 (EP,US); C07D213/75 (EP,US); C07D213/81 (EP,US); C07D215/12 (EP,US); C07D221/20 (EP,US); C07D231/14 (EP,US); C07D231/18 (EP,US); C07D233/36 (EP,US); C07D233/38 (EP,US); C07D233/68 (EP,US); C07D235/30 (EP,KR,US); C07D239/20 (EP,US); C07D239/22 (EP,US); C07D241/08 (EP,US); C07D241/12 (EP,US); C07D249/18 (EP,US); C07D257/04 (EP,US); C07D261/18 (EP,US); C07D277/56 (EP,US); C07D295/155 (EP,US); C07D295/192 (EP,US); C07D307/68 (EP,US); C07D317/68 (EP,US); C07D333/70 (EP,US); C07D401/04 (EP,US); C07D401/12 (EP,KR,US); C07D401/14 (EP,KR,US); C07D405/12 (EP,KR,US); C07D409/04 (EP,US); C07D409/12 (EP,KR,US); C07D417/04 (EP,US); C07D417/12 (EP,US); C07D471/04 (EP,US); C07D471/10 (EP,US); C07D487/04 (EP,US); C07D487/08 (EP,US); C07D487/10 (EP,US); C07D491/10 (EP,US); C07D493/08 (EP,US); C07D495/10 (EP,US); C07D498/04 (EP,US); C07D513/10 (EP,US); Y02A50/30 (US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/32]
Former [2022/01]	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Extension states	BA	Not yet paid
	ME	Not yet paid
Validation states	MA	Not yet paid
	MD	Not yet paid
Title	German:	ALPHA-CINNAMID-VERBINDUNGEN UND ZUSAMMENSETZUNGEN ALS HDAC8-INHIBITOREN	[2022/01]
	English:	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS	[2022/01]
	French:	COMPOSÉS ALPHA-CINNAMIDIQUES ET COMPOSITIONS COMME INHIBITEURS DE HDAC8	[2022/01]
Examination procedure	05.07.2022	Amendment by applicant (claims and/or description)
	05.07.2022	Examination requested [2022/32]
	05.07.2022	Date on which the examining division has become responsible
	16.06.2023	Despatch of a communication from the examining division (Time limit: M06)
	03.01.2024	Application deemed to be withdrawn, date of legal effect [2024/21]
	23.01.2024	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2024/21]
Parent application(s) Tooltip	EP16711758.9 / EP3268358
Fees paid	Renewal fee
	23.08.2021	Renewal fee patent year 03
	23.08.2021	Renewal fee patent year 04
	23.08.2021	Renewal fee patent year 05
	23.08.2021	Renewal fee patent year 06
	25.03.2022	Renewal fee patent year 07
	23.03.2023	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A]US2004077726 (WATKINS CLARE [GB], et al) [A] 1-13 * examples 157, 161, 165, 225; claims 1, 134, 140 *;
		[A]WO2011103189 (UWM RES FOUNDATION INC [US], et al) [A] 1-13 * page 73 *;
		[I]WO2013101600 (PHARMACYCLICS INC [US]) [I] 1-13 * claims 1, 33, 38; table B; compounds 6-32 *;
		[X]WO2015026935 (HOPE CITY [US], et al) [X] 1,3,9-13 * page 70; claim 1; table 3; compound 21 *;
		[A] - MAI A ET AL, "SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-,3-, AND 4-ACYLAMINOCINNAMYL-N-HYDROXYAMIDES AS NOVEL SYNTHETIC HDAC INHIBITORS", MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, NL, (20050301), vol. 1, no. 3, doi:10.2174/1573406053765431, ISSN 1573-4064, pages 245 - 254, XP008059889 [A] 1-13 * compounds 1a-1c, 1e-1g * DOI: http://dx.doi.org/10.2174/1573406053765431
	by applicant	US5262564
		- GOBERT, M. et al., Cancer Res, (20090000), vol. 69, pages 2000 - 2009
		- MATALON et al., Mol Med, (20110000), vol. 17, no. 5-6, pages 466 - 472
		- S. BERGE et al., Journal of Pharmaceutical Sciences, (19770000), vol. 66, no. 1, pages 1 - 19
		- P. GOULD, International J. of Pharmaceutics, (19860000), vol. 33, pages 201 - 217
		- The Orange Book, Food & Drug Administration

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p